Posts Tagged ‘biotech’

Financial Growing Pains of a Biotech | The Scientist Magazine(R)

Sunday, August 27th, 2017

The Man Who Kicked Off the Biotech Revolution – Issue 44: Luck – Nautilus

Tuesday, January 31st, 2017

The Man Who Kicked Off…#Biotech by @CarlZimmer H Smith for discovering restriction enzymes + a history of the term

“Trying to make sense of the failure, Wilcox suggested to Smith that the bacteria were destroying the viral DNA. He based his suggestion on a hypothesis proposed a few years earlier by Werner Arber, a microbiologist at the University of Geneva. Arber speculated that enzymes could restrict the growth of viruses by chopping up their DNA, and dubbed these hypothetical molecules “restriction enzymes.”” “}}

The Billion Dollar Pharma Startup that Silicon Valley Has Totally Missed

Saturday, January 21st, 2017

The…Pharma Startup…Silicon Valley Has Totally Missed Run by QVT alum; focuses on better incentivizing scientists

UPDATED: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus

Tuesday, July 14th, 2015

$BMY rips up its R&D group…800-plus [affected] Trend of pruning spoke cities & growing #hub ones HT @JorgensenWL

“Bristol-Myers Squibb’s big reorganization fits into the industry’s new model for R&D. Large, scattered groups are out as big
organizations gravitate toward the big hubs. GlaxoSmithKline ($GSK) and Amgen ($AMGN) have offered two recent examples of that trend, which has benefited hubs like Boston/Cambridge and the Bay Area while inflicting painful cuts in outlying areas. Biopharma companies are also concentrating on core areas, sometime shedding early-stage work–reflected in Merck’s ($MRK) recent downsizing at the newly acquired Cubist and the big asset swap that occurred between GlaxoSmithKline and Novartis ($NVS).”